SFRP4 and ovarian cancer: The loss of expression not only from borderline tumors towards aggressive phenotype ovarian cancers but also from what is supposed to be the site of origin (fimbrial end of the fallopian tube) towards the cancer also strengthens the proposed putative inhibitory function of SFRP4 within the Wnt signaling pathway.